Passage Bio Inc (NAS:PASG)
$ 0.9 -0.11 (-10.89%) Market Cap: 55.59 Mil Enterprise Value: 3.95 Mil PE Ratio: 0 PB Ratio: 0.76 GF Score: 33/100

Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion Transcript

Mar 07, 2023 / 03:30PM GMT
Release Date Price: $1.26 (+2.44%)
Brendan Mychal Smith
TD Cowen, Research Division - Associate

(technical difficulty) Annual TD Cowen 43rd Conference. It's my pleasure today to co-moderate the orphan neurology Corporate panel with my colleague, Anvita Gupta and joined by esteemed panel of industry titans here. We have one swap out, Gary Romano, CMO of Alector; we also have Essra Ridha, the CMO of AVROBIO; Ryan Watts, CEO of Denali Therapeutics; Bobby Gaspar, CEO of Orchard Therapeutics; William Chou, the CEO of Passage Bio; and Emil Kakkis, the President and CEO of Ultragenyx.

So most of you are probably familiar with the general format at this point, but we're going to pitch a few thematic questions on the orphan neurology space, so the panel is kind of split it up between them, and then we'll kind of dive into some company-specific questions and more of round-robin later on. So with that said, let's dive right in.

Questions & Answers

Brendan Mychal Smith
TD Cowen, Research Division - Associate

So obviously, a lot going on orphan neurology space, the breadth of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot